Cautious Outlook on Alnylam Pharma Amid Mixed Financial Results and Market Uncertainties

Mani Foroohar, an analyst from Leerink Partners, reiterated the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price target was raised to $245.00.

Mani Foroohar has given his Hold rating due to a combination of factors related to Alnylam Pharma’s recent performance and future prospects. The company announced its first-quarter earnings for 2025, which were largely in line with expectations, and reiterated its full-year guidance for product sales and profitability. While the launch of Amvuttra following FDA approval is progressing, with significant formulary coverage and patient initiation, there remain uncertainties regarding its market share among first-line and switch patients.
Additionally, while the early progress in formulary inclusion is promising, there are still unresolved questions about physician adoption of the buy-and-bill model, which could impact future performance. The financial results showed mixed outcomes, with some products meeting expectations and others falling short. These factors contribute to a cautious outlook, leading to a Hold rating as the market awaits more clarity on these issues over the coming quarters.

In another report released on May 1, Morgan Stanley also maintained a Hold rating on the stock with a $287.00 price target.

ALNY’s price has also changed slightly for the past six months – from $273.910 to $255.130, which is a -6.86% drop .